
Matthew Breeggemann, MD, of UCSF discusses genetic testing, risk stratification, and the future of personalized CKD management in 2026.

Matthew C. Breeggemann, MD is a nephrologist who cares for patients with kidney disease. He is medical director of UCSF's Kidney Stone Prevention Clinic, where he treats patients with a variety of kidney stone disorders in collaboration with the department of urology.

Matthew Breeggemann, MD, of UCSF discusses genetic testing, risk stratification, and the future of personalized CKD management in 2026.

Matthew Breeggemann, MD, UCSF nephrologist, explains how CKD is diagnosed, monitored, and why new CKD therapies take years to reach patients.

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.